MetaCap

Azitra (AZTR) vs NeuroSense Therapeutics (NRSN)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

NeuroSense Therapeutics is the larger company by market cap ($3.2 million vs $3.1 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

AZTR+291.52%NRSN-66.49%
+1115%+496%-123%
Oct 7, 20261 yearNov 20, 2026
AZTR+297.84%NRSN-65.03%
+520%+214%-93%
Oct 5, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

AZTR versus NRSN key metrics
MetricAZTRNRSN
Share price$0.5168$1.28
Market cap$3.13M$3.19M
1-day change-2.75%+1.59%
EPS (TTM)$-12.40$-47.10
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$0—
Revenue growth (YoY)-100.00%—
Net income (latest FY)$-10.96M$-11.13M
52-week high$3.91$24.80
52-week low$0.5086$1.10
Distance from 52-week high-86.78%-94.84%
Analyst consensusbuystrong_buy
Avg. price target upside+29.64%+7503.91%
Average volume2.65M31.57K
Shares outstanding6.06M2.49M
Employees1317
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Azitra

AZTR stock →

Azitra, Inc., an early-stage clinical biopharmaceutical company, develops therapies for precision dermatology using engineered proteins and topical live biotherapeutic products to treat skin diseases in the United States. The company develops ATR-04, a genetically modified strain of S.

Health Care · Biotechnology: Pharmaceutical Preparations · 13 employees

About NeuroSense Therapeutics

NRSN stock →

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease.

Health Care · Biotechnology: Pharmaceutical Preparations · 17 employees

AZTR vs NRSN FAQ

Which is bigger, Azitra or NeuroSense Therapeutics?

NeuroSense Therapeutics (NRSN) is larger, with a market capitalization of $3.19M compared with $3.13M for Azitra (AZTR).

Are Azitra and NeuroSense Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons